Search
Ferrimannitol ovalbumin
go.drugbank.com/drugs/DB15824InvestigationalFerrimannitol-ovalbumin (FMOA) is an adduct between ovalbumin and the complex Fe(III)-mannitol.
Pyruvaldehyde
go.drugbank.com/drugs/DB03587ExperimentalAn organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. … It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals. [PubChem]
N-(3-carboxypropanoyl)-L-norvaline
go.drugbank.com/drugs/DB08554ExperimentalThese are compounds containing an alpha amino acid which bears an acyl group at his terminal nitrogen atom.
Perflubron
go.drugbank.com/drugs/DB05791InvestigationalPerflubron (Oxygent) is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.
Ganstigmine
go.drugbank.com/drugs/DB06525ExperimentalGanstigmine is an orally active, geneserine derived, carbamate-based acetylcholinesterase inhibitor developed for the treatment of Alzheimer's disease.
Lasalocid
go.drugbank.com/drugs/DB11423ExperimentalVet approvedLasalocid is an agent that presents antibacterial and coccidiostat activities. It is produced by strains of _Streptomyces lasaliensis_.
AVI-014
go.drugbank.com/drugs/DB17086InvestigationalAVI-014 is an egg white-derived transgenic, glycosylated, recombinant human granulocyte colony-stimulating factor (G-CSF).[A274441]
AVP-21D9
go.drugbank.com/drugs/DB17798InvestigationalAVP-21D9 is a fully human anthrax monoclonal antibody that is being investigated as an anthrax antitoxin.[A259522]
Prizloncabtagene autoleucel
go.drugbank.com/drugs/DB18623InvestigationalC-CAR039 is an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR.
Synonyms: an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CARCTX120
go.drugbank.com/drugs/DB18625InvestigationalCTX120 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting B-cell maturation antigen.